🇺🇸 FDA
Pipeline program

Nemtabrutinib

1026-011

Phase 3 small_molecule active

Quick answer

Nemtabrutinib for Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials